---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-014178"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:56:07.151085+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics raises $4.4M via warrant exercise inducement; issues new warrants

## Summary
- Holders exercised 689,680 existing warrants at reduced price of $6.20/share for $4.4M gross proceeds.
- In exchange, Company issued new Series C and Series D warrants to purchase up to 689,680 shares each at $6.20.
- Series C warrants exercisable for 5 years; Series D for 18 months; Placement agent got warrants at $7.75.
- Proceeds used for general corporate purposes; H.C. Wainwright acted as exclusive placement agent.
- Existing warrants (Oct 2022, Nov 2023, Jan 2024) had exercise prices of $116.25, $22.545, and $22.545.

## SEC filing metadata
- accession: 0001437749-24-014178
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774924014178/0001437749-24-014178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774924014178/atxi20240501_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-014178
- JSON: https://secwatch.observer/filing/0001437749-24-014178.json
- Plain text: https://secwatch.observer/filing/0001437749-24-014178.txt

## Key facts
- Material Agreements
  AVENUE THERAPEUTICS, INC. entered into Inducement Letters with certain investors (the October 2022 Investors, November 2023 Investors, and January 2024 Investors) valued at approximately $4.4 million (effective 2024-04-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors (the October 2022 Investors, November 2023 Investors, and January 2024 Investors)
  - Value: approximately $4.4 million
  - Effective: 2024-04-28
  source text: On April 28, 2024, Avenue Therapeutics, Inc. (the “ Company ”) entered into inducement offer letter agreements (the “ Inducement Letters ”) with (i) certain investors (the “ October 2022 Investors ”) that hold certain outstanding warrants to purchase up to an aggregate of 27,271 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), originally issued to the October 2022 Investors on October 11, 2022 (the “ October 2022 Warrants ”); (ii) certain investors (the “ November 2023 Investors ”) that hold certain outstanding Series A and Series B warrants to purchase up to an aggregate of 221,333 shares of Common Stock, originally issued to the November 2023 Investors on October 31, 2023 (the “ November 2023 Warrants ”); and (iii) certain investors (the “ January 2024 Investors ” and, collectively with the October 2022 Investors and November 2023 Investors, the “ Holders ”) that hold certain outstanding Series A and Series B warrants to purchase up to an agg
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774924014178/0001437749-24-014178-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.